Abeona Therapeutics (ABEO) Net Equity Issued and Repurchased (2016 - 2025)

Abeona Therapeutics' Net Equity Issued and Repurchased history runs 9 years deep, the most recent figure standing at $10.5 million for Q2 2025.

• In Q2 2025, Net Equity Issued and Repurchased rose 196.22% year-over-year to $10.5 million; the TTM figure through Dec 2025 stood at $17.3 million (up 11.79% YoY), while the FY2025 annual figure was $17.3 million, up 11.79% from the prior year.
• Net Equity Issued and Repurchased for Q2 2025 stood at $10.5 million, up from $6.8 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $28.4 million in Q4 2022, with the low at -$18.3 million in Q3 2022.
• The 5-year median for Net Equity Issued and Repurchased is $5.4 million (2021), against an average of $4.9 million.
• Peak annual rise in Net Equity Issued and Repurchased reached 7971.31% in 2022, while the deepest fall reached 55490.91% in 2022.
• Abeona Therapeutics' Net Equity Issued and Repurchased stood at $352000.0 in 2021, then soared by 7971.31% to $28.4 million in 2022, then plunged by 72.6% to $7.8 million in 2023, then declined by 29.18% to $5.5 million in 2024, then soared by 90.48% to $10.5 million in 2025.
• Business Quant data shows ABEO's Net Equity Issued and Repurchased at $10.5 million in Q2 2025, $6.8 million in Q1 2025, and $5.5 million in Q4 2024.